This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Patterson Cos. (PDCO) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Patterson Cos. (PDCO) delivered earnings and revenue surprises of 20% and 3.85%, respectively, for the quarter ended April 2023. Do the numbers hold clues to what lies ahead for the stock?
Phreesia (PHR) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Phreesia (PHR) delivered earnings and revenue surprises of 7.69% and 2.56%, respectively, for the quarter ended January 2023. Do the numbers hold clues to what lies ahead for the stock?
ImmunoPrecise Antibodies Ltd. (IPA) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
ImmunoPrecise Antibodies Ltd. (IPA) delivered earnings and revenue surprises of -16.67% and 6.19%, respectively, for the quarter ended January 2023. Do the numbers hold clues to what lies ahead for the stock?
Tabula Rasa Healthcare (TRHC) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Tabula Rasa Healthcare (TRHC) delivered earnings and revenue surprises of -200% and 0.22%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Schrodinger, Inc. (SDGR) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Schrodinger, Inc. (SDGR) delivered earnings and revenue surprises of 22% and 16.74%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Is Intellia Therapeutics (NTLA) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Intellia Therapeutics, Inc. (NTLA) and Centogene N.V. (CNTG) have performed compared to their sector so far this year.
Phreesia (PHR) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Phreesia (PHR) delivered earnings and revenue surprises of 13.64% and 2.73%, respectively, for the quarter ended October 2022. Do the numbers hold clues to what lies ahead for the stock?
Sema4 Holdings Corp. (SMFR) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Sema4 Holdings Corp. (SMFR) delivered earnings and revenue surprises of -5.26% and 8.66%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Sangoma Technologies Corporation (SANG) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Sangoma Technologies Corporation (SANG) delivered earnings and revenue surprises of 62.50% and 2.01%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Outset Medical, Inc. (OM) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Outset Medical, Inc. (OM) delivered earnings and revenue surprises of 1.41% and 9.51%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Computer Programs and Systems (CPSI) Q3 Earnings Lag Estimates
by Zacks Equity Research
Computer Programs and Systems (CPSI) delivered earnings and revenue surprises of -13.64% and 0.93%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Icosavax, Inc. (ICVX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Icosavax, Inc. (ICVX) delivered earnings and revenue surprises of -3.64% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Privia Health (PRVA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Privia Health (PRVA) delivered earnings and revenue surprises of -400% and 7.53%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Strata Skin Sciences, Inc. (SSKN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Strata Skin Sciences, Inc. (SSKN) delivered earnings and revenue surprises of -25% and 12.27%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Azenta (AZTA) Q3 Earnings Beat Estimates
by Zacks Equity Research
Brooks (AZTA) delivered earnings and revenue surprises of 50% and 0.05%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Clover Health Investments, Corp. (CLOV) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Clover Health Investments, Corp. (CLOV) delivered earnings and revenue surprises of 4.35% and 0.62%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Phreesia (PHR) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Phreesia (PHR) delivered earnings and revenue surprises of 9.17% and 1.49%, respectively, for the quarter ended April 2022. Do the numbers hold clues to what lies ahead for the stock?
Change Healthcare (CHNG) Q4 Earnings Miss Estimates
by Zacks Equity Research
Change Healthcare (CHNG) delivered earnings and revenue surprises of -9.30% and 1.78%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Gain Therapeutics, Inc. (GANX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Gain Therapeutics, Inc. (GANX) delivered earnings and revenue surprises of 17.65% and 25%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Centogene N.V. (CNTG) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Centogene N.V. (CNTG) delivered earnings and revenue surprises of -83.05% and 11.58%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for September 10th
by Zacks Equity Research
CNTG, JOAN, STRT, ZNGA, and PTVE have been added to the Zacks Rank #5 (Strong Sell) List on September 10, 2021
Centogene N.V. (CNTG) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Centogene N.V. (CNTG) delivered earnings and revenue surprises of -73.08% and 62.19%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Centogene N.V. (CNTG) Stock Jumps 7.5%: Will It Continue to Soar?
by Zacks Equity Research
Centogene N.V. (CNTG) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks Industry Outlook Highlights: Computer Programs and Systems, Centogene and Cerner
by Zacks Equity Research
Zacks Industry Outlook Highlights: Computer Programs and Systems, Centogene and Cerner
3 Medical Info System Stocks to Bank on Despite Decline in COVID-19 Cases
by Urmimala Biswas
The Zacks Medical Info Systems industry is gaining from growing demand for digital healthcare support. However, drop in COVID-19 cases might disrupt this uptrend. Industry players CPSI, CNTG and CERN are set to gain the most.